Open AccessSuccessful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
Author(s) -
Morten Hindsø,
Christoffer Martinussen,
Maria S. Svane,
Simon Veedfald,
Birthe Gade-Rasmussen,
Torben Hansen,
Sten Madsbad
Publication year - 2021
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2021_002352
Subject(s) - sulfonylurea , medicine , agonist , sulfonylurea receptor , diabetes mellitus , type 2 diabetes , combination therapy , glucagon like peptide 1 receptor , endocrinology , receptor , glibenclamide
Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months’ follow-up.